Akashi Therapeutics has been given the FDA go-ahead to restart tests for its Duchenne muscular dystrophy candidate HT-100 (delayed-release halofuginone), just…

Quiet upstart BioClin Therapeutics has raised $30 million in a Series B funding round, taking its total to $59 million since its founding, as it aims to push…

Last year, Cardiff, U.K.-based Verona secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic for work on its PDE3/PDE4…

Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

The FDA warned of a higher rate of cardiac events in patients receiving Abbott's Absorb stent compared to those treated with a metal stent.

Arriving later to the PCSK9 inhibitor market could actually be beneficial to Alnylam and The Medicines Company, say analysts.